Bristol Myers Squibb Raises 2024 Non-GAAP Guidance
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Bristol Myers Squibb (BMY) increased portions of its 2024 line-item guidance. The company now expects: non-GAAP EPS in a range of $0.60 – $0.90, revised from prior guidance range of $0.40 – $0.70; and total revenues at upper end of low single- digit range, revised fro
:max_bytes(150000):strip_icc():format(jpeg)/FPM-Best-Personal-Loans-Methodology-Recirc-468fcab5bfa84ae485bd56843cf5c0eb.png "How We Review and Rate Personal Loan Lenders")
:max_bytes(150000):strip_icc():format(jpeg)/PropertyValuation-4ecdfe3a87144fe998087ef433f49c13.jpeg "Is There a Gender Gap in Home Equity Loans?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1346781100-2724c28da6b2479b88db9d1337ebe926.jpg "Buy Now, Pay Later or Rent-to-Own: Which Is the Smarter Way to Pay for Purchases?")